Octaplaslg (Human Plasma Protein)

Human Plasma Protein, the active ingredient in Octaplaslg, is a plasma‑derived protein concentrate presented as a liquid for intravenous use. It supports hemostasis in patients experiencing significant blood loss, particularly during surgery or trauma. GNH USA supplies Octaplaslg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Octaplaslg is used in clinical situations that require rapid restoration of coagulation factors within the plasma‑derived protein family. - Massive transfusion protocols: Provides essential clotting factors to control bleeding during massive transfusion. - Cardiac surgery: Helps maintain hemostasis during cardiopulmonary bypass. - Liver transplantation: Supplies coagulation proteins needed for patients with impaired liver function.

Adverse reactions to Octaplaslg are generally infrequent but may occur.

Common Side Effects: - Mild fever: Low‑grade temperature elevation observed in some recipients. - Headache: Transient headache reported during or after infusion. - Nausea: Occasional nausea without vomiting. - Chills: Mild shivering during the infusion. - Rash: Small erythematous skin lesions at the infusion site.

Serious or Rare Side Effects: - Anaphylactic reaction: Severe allergic response requiring immediate medical intervention. - Transfusion‑related acute lung injury (TRALI): Acute respiratory distress following infusion. - Hemolytic transfusion reaction: Destruction of red blood cells due to incompatibility. - Sepsis: Bacterial contamination leading to systemic infection. - Thromboembolic events: Formation of clots in vessels causing organ compromise.

When using Octaplaslg, clinicians should observe several safety measures. - Verify patient identity: Confirm matching blood type and compatibility before infusion. - Monitor vital signs: Observe blood pressure, heart rate, and oxygen saturation throughout the procedure. - Assess for allergies: Review patient history for prior reactions to plasma products. - Use aseptic technique: Maintain sterile conditions to prevent contamination. - Adjust for volume overload: Consider cardiac status in patients at risk of fluid overload. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg may interact with other therapies that affect coagulation or immune response.

Major Interactions (Avoid): - Warfarin: Concurrent use can excessively prolong clotting times. - Direct oral anticoagulants (DOACs): May increase bleeding risk when combined. - High‑dose aspirin or other NSAIDs: Potentiates anticoagulant effect.

Moderate Interactions (Monitor Closely): - Heparin: Requires careful monitoring of activated partial thromboplastin time. - Immunoglobulin therapy: May alter immune response and affect plasma protein clearance. - Corticosteroids: May mask early signs of transfusion reactions.